Health Innovation Manchester has continued to enhance and develop its operating model in order to best support the needs of the system during the COVID-19 pandemic. HInM has been well-placed to respond to the needs of the system as the single organisation working across academia, industry engagement and aligned to the needs of the Greater Manchester system. GM has been able to rapidly work together to adapt to the changing situation and align behind the same aims and objectives. This partnership working has been vital to delivering innovation during COVID-19.

The HInM Board, comprising leaders from the health and care system, academia and industry, has played a pivotal role in setting our strategies and plans against meeting GM priorities, enabling us to accelerate innovation which will result in improving outcomes for citizens, transform pathways and contribute to economic growth. We have worked closely with the Board and partners across GM to define a new business plan (which will be published summer 2021) and agree the priorities for health innovation across GM, which we are using to inform the delivery portfolio for the year ahead:

1. Accelerating innovation at pace and scale
2. Delivering traditional and real world studies
3. Data science, pathway analysis and transformation
4. Place-based transformation

We have also considerably strengthened our innovation method and pipeline approach by combining our unique skills and capabilities, to develop a deep understanding of citizen need, clearly define problems and co-design innovative solutions. This then leads to deployment at scale, leading to transformation of care pathways and citizen outcomes.

By combining our unique skills and capabilities, we will develop a deep understanding of citizen need, clearly define problems and co-design innovative solutions. These are deployed at scale and lead to transformation of care pathways and citizen outcomes.

During 2020-2021, we have also led the roll out of the pipeline approach to innovation across the AHSN Network, including the mechanisms by which proposals are identified, assessed, prioritised, and supported through to deployment and adoption at scale. This work has included a baseline survey across all 15 AHSNs to identify the current pipeline approaches to areas of consistency and diversity in adoption approaches. Following the survey, a phased rollout approach was implemented, with a series of workshops and development plans created for each AHSN to support rollout. AHSNs have also been supported to adapt the model to their local ecosystems and current operating models.

Rowena Burns, Chair of Health Innovation Manchester
Professor Ben Bridgewater, Chief Executive Health Innovation Manchester
Amanda Risino, Chief Operating Officer, Health Innovation Manchester
Professor Peter Clayton, Chief Academic Officer, Health Innovation Manchester
Sir Howard Bernstein, Strategic Advisor
Dr Helen Routh, Strategic Advisor
Richard Topliss, Chair of The Growth Company

Eamonn Boylan, Chief Executive, Greater Manchester Combined Authority
Sir Mike Deegan, Chief Executive, Manchester University NHS Foundation Trust
Steve Dixon, Chief Accountable Officer, NHS Salford Clinical Commissioning Group
Raj Jain, Chief Executive, Northern Care Alliance NHS Group
Sir Richard Leese, Chair of the Greater Manchester Health and Social Care Partnership
Professor Graham Lord, Vice President The University of Manchester and Dean of Faculty of Biology, Medicine and Health
Professor Malcolm Press, Vice-Chancellor, Manchester Metropolitan University
Sarah Price, Interim Chief Officer Greater Manchester Health and Social Care Partnership
Joanne Roney, Chief Executive, Manchester City Council
Professor Dame Nancy Rothwell, President and Vice Chancellor, The University of Manchester
Dr Jeffrey Schryer, Chair, NHS Bury Clinical Commissioning Group
Roger Spencer, Chief Executive, The Christie NHS Foundation Trust
John Stageman, OBE Chairman, Bionow

We would like to thank Lord Peter Smith for his time on the board and wish him well in the future.

Find out more about our board

Professor Ben Bridgewater, Chief Executive
Professor Peter Clayton, Chief Academic Officer
Amanda Risino, Chief Operating Officer
Dr Tracey Vell, Clinical Director
Professor Ian Bruce, Academic Director
Guy Lucchi, Digital Innovation Director
Laura Rooney, Director of Corporate Affairs and Strategy

Find out more about our Executive Team

Our financial duty is to breakeven year on year.
2019-20 Figures include 6 months activity for GM ARC from 1 October.
2019, 2020/21 includes a full year of ARC activity.

Use the image links below to move between the different sections of the report.